-
China’s SAMR Proposes Antitrust Guidelines to Regulate Pharmaceutical Industry
•
The State Administration for Market Regulation (SAMR) in China has unveiled a draft proposal for “Antitrust Guidelines for the Pharmaceutical Industry” and is currently soliciting public feedback until August 23, 2024. This comprehensive document, encompassing 55 articles across seven sections, is designed to clarify the foundational principles of anti-monopoly law…
-
China Unveils Comprehensive Plan to Tackle Unhealthy Practices in Pharma and Healthcare
•
The National Health Commission (NHC), National Healthcare Security Administration (NHSA), National Medical Products Administration (NMPA), and a total of 14 ministries have issued the “Key Points for Correcting Unhealthy Practices in the Field of Pharmaceutical Procurement and Sales and Medical Services in 2024.” The document aims to address key personnel…
-
Hubei Province Issues Anti-Commercial Bribery Guidelines for Medical Industry
•
The Hubei provincial market supervision administration has released a set of guidelines titled “Anti-Commercial Bribery Compliance Management” for medical industry enterprises within the province. The document is designed to guide pharmaceutical companies in developing a culture of compliance and fair competition, establishing robust anti-bribery management systems, and mitigating legal risks…
-
Shanghai Pharmaceuticals Hit with Anti-Monopoly Fine by Shanghai Market Supervision Bureau
•
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company based in China, has recently come under regulatory scrutiny. Following the earlier reports that C-suite executives were under investigation, the company has now announced receiving an Administrative Penalty Decision letter from Shanghai’s Market Supervision Administration regarding its wholly-owned…
-
NMPA Pilots Priority Review for Rare Disease Formula Foods, Aims to Reduce Approval Time
•
The National Medical Products Administration (NMPA) has initiated a pilot program to implement “Priority review and approval procedures applied to formula foods for rare diseases and special medical purposes that are urgently needed in clinical practice.” According to the People’s Daily, these procedures are expected to be incorporated into the…
